• Nonsteroidal AR inhibitor
    • FDA approved for treatment of prostate cancer and hirsutism. Clinical trials have shown minimum activity in AR-positive breast cancer.
    • Recommended dose: 50 mg PO daily
    • Half-life: 6 days
    • Metabolism: Substrate of CYP3A4
    • Common side effects: AST and ALT increase, hyperbilirubinemia, ALP increase, nausea, pain (bone, back, pelvis), anorexia, fatigue, diarrhea, hot flashes, limb edema
    Other topics in Targeted and Immunotherapy Agents